The Health Care M&A Monthly: JNJ Buys Crucell, NV–
Pays $2.4 Billion To Grow Vaccines Business Johnson & Johnson (NYSE: JNJ) recently announced plans to buy the remaining 82.1% that it does not already own of Crucell, NV (NASDAQ: CRXL), the Dutch vaccines company. The purchase price is $2.4 billion. This deal...The Health Care M&A Monthly: Biotech Sees Strong M&A Activity–
Nine Deals Announced In August Worth $21.0 Billion The Biotech industry posted strong results in the M&A market during August. Nine deals were announced worth a combined total of $20.989 billion. The top three deals involved purchases of biotech concerns by large...The Health Care M&A Monthly: Onex Corp. Buys ResCare–
Pays $390.0 Million For Behavioral Services Provider Canadian private equity firm Onex Corp. (TSX: OCX) made a bid in mid-August to acquire the remainder of ResCare (NASDAQ: RSCR). In the second largest Behavioral Health Care deal of the year, behind Universal Health...The Health Care M&A Monthly: A Midsummer’s Hospital Market–
Sector Posts Hot M&A Activity This Summer Since the passage of health care reform in mid-March, merger and acquisition activity in the Hospital sector has become robust. Prior to passage, 2010 posted only five deals involving five single hospitals for a combined...The Health Care M&A Monthly: Sanofi Courts Genzyme–
Opens Negotiations With $18.3 Billion Bid In what appears to be the industry’s worst-kept secret, Sanofi-Aventis (NYSE: SNY) has approached biotech giant Genzyme Corp. (NASDAQ: GENZ) with a takeover offer. Why it would do so, however, is no secret. Several of Sanofi’s...Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
